Entrada Therapeutics (TRDA) Return on Sales: 2023-2025
Historic Return on Sales for Entrada Therapeutics (TRDA) over the last 2 years, with Sep 2025 value amounting to -1.68%.
- Entrada Therapeutics' Return on Sales fell 194.00% to -1.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.68%, marking a year-over-year decrease of 194.00%. This contributed to the annual value of 0.31% for FY2024, which is 36.00% up from last year.
- Latest data reveals that Entrada Therapeutics reported Return on Sales of -1.68% as of Q3 2025, which was down 82.35% from -0.92% recorded in Q2 2025.
- Entrada Therapeutics' Return on Sales' 5-year high stood at 0.44% during Q2 2024, with a 5-year trough of -1.68% in Q3 2025.
- In the last 3 years, Entrada Therapeutics' Return on Sales had a median value of 0.14% in 2024 and averaged -0.17%.
- In the last 5 years, Entrada Therapeutics' Return on Sales soared by 36bps in 2024 and then plummeted by 194bps in 2025.
- Entrada Therapeutics' Return on Sales (Quarterly) stood at -0.05% in 2023, then soared by 36bps to 0.31% in 2024, then slumped by 194bps to -1.68% in 2025.
- Its last three reported values are -1.68% in Q3 2025, -0.92% for Q2 2025, and 0.14% during Q1 2025.